https://doi.org/10.4081/itjm.2024.1846

Pharmacological interactions in novel oral anticoagulants, statins, and hypertension drugs in patients treated with direct-acting antivirals for hepatitis C: a Delphi Consensus project

Vol. 18 No. 4 (2024)
Published: 25 November 2024
Direct-acting antivirals, hepatitis C, novel oral anticoagulants, statins, hypertension therapy
Abstract Views: 927
PDF: 318
SUPPLEMENTARY MATERIAL: 215
ACKNOWLEDGMENTS: 206
HTML: 102
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Ivan Gentile
https://orcid.org/0000-0002-5199-8451
Department of Clinical Medicine and Surgery, Federico II University of Naples, Italy.
Giancarlo Agnelli
Internal, Vascular and Emergency Medicine-Stroke Unit, University of Perugia, Italy.
Angelo Avogaro
Section of Diabetes and Metabolic Diseases, Department of Medicine, University of Padua, Italy.
Claudio Borghi
Internal Medicine, Department of Medical and Surgical Sciences, Policlinic S. Orsola-Malpighi, University of Bologna, Italy.
Alessia Ciancio
Gastroenterology Unit, Department of Internal Medicine, Città della Salute e della Scienza di Torino, University of Turin, Italy.
Ernesto Claar
Liver Unit, Ospedale Evangelico Betania, Naples, Italy.
Patrizio Pasqualetti
patrizio.pasqualetti@uniroma1.it
https://orcid.org/0000-0001-5560-1979
Section of Health Statistics and Biometry, Department of Public Health and Infectious Diseases, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Italy.
Pasquale Perrone Filardi
Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy.

To date, no retrospective or real-world studies have comprehensively examined the interactions between direct-acting antivirals (DAAs) and widely used medications such as novel oral anticoagulant, statins, and antihypertensive agents. However, clinical experience from key opinion leaders may guide physicians in managing these interactions in patients undergoing DAA treatment. This study aims to elucidate the interactions between DAAs and commonly prescribed drugs in patients with prevalent comorbidities (e.g., type II diabetes, hypertension, and dyslipidemia), with a particular focus on those receiving polytherapy with cardiovascular drugs while undergoing DAA treatment for hepatitis C. The clinicians’ experience was combined with input from a qualified expert panel using a Consensus Delphi approach. The findings of this study offer essential and practical recommendations that can be readily applied in everyday clinical practice, helping physicians in managing hepatitis C virus patients undergoing DAA therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Licata A, Minissale MG, Giannitrapani L, et al. Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohort. Intern Emerg Med 2022;17:43-51. DOI: https://doi.org/10.1007/s11739-021-02741-9
Pawlotsky JM, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: f inal update of the series. J Hepatol 2020;73:1170-218. DOI: https://doi.org/10.1016/j.jhep.2020.08.018
HEP Drug Interactions. Interaction checker. Available from: www.hep-druginteractions.org.
Fagiuoli S, Toniutto P, Coppola N, et al. Italian real-world analysis of the impact of polypharmacy and aging on the risk of multiple drug-drug interactions (DDIs) in HCV patients treated with pangenotypic direct-acting antivirals (pDAA). Ther Clin Risk Manag 2023;19:57-65. DOI: https://doi.org/10.2147/TCRM.S394467
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2021;42:3227-337. DOI: https://doi.org/10.1093/eurheartj/ehab484
Butt AA, Yan P, Shuaib A, et al. Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events. Gastroenterology 2019;156:987-96.e8. DOI: https://doi.org/10.1053/j.gastro.2018.11.022
Borghi C, Ciancio A, Gentile I, et al. Evaluation of drug interactions in patients treated with DAAs for hepatitis C therapy with comorbidities and cardiovascular issues—a Delphi consensus project. J Clin Med 2022;11:6946. DOI: https://doi.org/10.3390/jcm11236946
Linstone H, Turoff M. The Delphi method. Techniques and applications. ©2002 Murray Turoff and Harold A. Linstone. https://www.foresight.pl/assets/downloads/publications/Turoff_Linstone.pdf.
Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376-80. DOI: https://doi.org/10.1136/bmj.311.7001.376
Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 2014;67:401-9. DOI: https://doi.org/10.1016/j.jclinepi.2013.12.002
Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. Int J Forecast 1999;15:353-75. DOI: https://doi.org/10.1016/S0169-2070(99)00018-7
Graham B, Regehr G, Wright JG. Delphi as a method to establish consensus for diagnostic criteria. J Clin Epidemiol 2003;56:1150-6. DOI: https://doi.org/10.1016/S0895-4356(03)00211-7
Yamashita T, Millar RJ. Likert scale. In: Gu D, Dupre ME, eds. Encyclopedia of Gerontology and Population Aging. Cham, Switzerland: Springer; 2021. pp 2938-41. DOI: https://doi.org/10.1007/978-3-030-22009-9_559
Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCLA appropriateness method user’s manual. Available from: https://www.rand.org/pubs/monograph_reports/MR1269.html. Accessed in: June 2023.
Mangia A, Scaglione F, Toniutto P, et al. Drug-drug interactions in Italian patients with chronic hepatitis C treated with pangenotypic direct acting agents: insights from a real-world study. Int J Environ Res Public Health 2021;18:7144. DOI: https://doi.org/10.3390/ijerph18137144
Thi Thu PN, Hoang Van D, Ngo Thi Quynh M, et al. Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: a prospective cohort study. PLoS One 2023;18:e0290235. DOI: https://doi.org/10.1371/journal.pone.0290235
Cachay ER, Mena A, Morano L, et al. Hepatitis C treatment outcomes in persons with HIV and decompensated cirrhosis using a collaborative multidisciplinary HIV-centered approach. J Int Assoc Provid AIDS Care 2021;20:23259582211024771. DOI: https://doi.org/10.1177/23259582211024771

How to Cite

Gentile, I., Agnelli, G., Avogaro, A., Borghi, C., Ciancio, A., Claar, E., Pasqualetti, P., & Perrone Filardi, P. (2024). Pharmacological interactions in novel oral anticoagulants, statins, and hypertension drugs in patients treated with direct-acting antivirals for hepatitis C: a Delphi Consensus project. Italian Journal of Medicine, 18(4). https://doi.org/10.4081/itjm.2024.1846
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.